Tissium is a mission-driven medical device company founded in 2013, headquartered in Paris, with a production facility in Roncq (near Lille) and an office in Boston. We are dedicated to creating a new era of body repair by leveraging our biopolymer platform to develop innovative solutions in surgery for a positive impact on patients' lives.
Tissium's technology is based on research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital), who co-founded the company with Christophe Bancel (CEO) and Maria Pereira (Deputy CEO & Chief Innovation Officer).
We are developing polymers for atraumatic tissue repair in various applications. Today, these polymers are used for sutureless nerve repair, hernia repair, and cardiovascular sealing.
Since our inception, we have raised a total of 170 million euros. Our latest fundraising round, which concluded in April 2023, resulted in 50 million euros in additional funding. This infusion of capital provides us with the necessary resources to finance the commercialization of our first products.
We are preparing for the early-2027 European launch of ECLIPSIUM®, a novel technology designed to advance atraumatic hernia repair. This is a rare opportunity to be part of a launch from its earliest stages, working closely with the Franchise Director, senior leadership, leading surgeons, Key Opinion Leaders, and commercial partners across Europe.
Reporting to the Franchise Director, you will be the central point of coordination for the ECLIPSIUM® European launch. You will turn the franchise strategy into clear, actionable plans, drive launch readiness across priority markets (Belgium, Germany, Switzerland and others), and make sure every workstream delivers on time. You will own key launch tools and workstreams, and gain broad exposure to Regulatory, Market Access, Clinical affairs, Sales and Finance.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function.
Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas.
Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices.
We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.